Illumina Inc. stock falls despite strong rebound from mid-2025 lows

Illumina Inc. stock (ISIN US4523271090) is trading around USD 207.13 per share as of September 1, 2026, reflecting a sharp recovery of roughly 89.6 percent from the USD 109.30 level recorded on July 25, 2025, according to data compiled by StockInvest.us.

Valuation debate around Illumina stock

On September 1, 2026, Illumina shares fell 3.0 percent to a price of USD 207.13, a move that has intensified the debate over whether the current valuation is justified. According to an analysis published by GuruFocus on September 1, 2026, a proprietary GF Value estimate puts Illumina’s intrinsic value at USD 132.60 per share, notably below the market price of USD 207.13.

The same valuation review highlights that at USD 207.13 Illumina trades at a premium of about 56.2 percent to the GF Value estimate, suggesting that expectations for future growth in genomic sequencing and oncology applications are heavily reflected in the share price. For investors, this gap between market price and intrinsic value estimates underlines the importance of scrutinizing both cash flow generation and earnings metrics rather than focusing solely on headline revenue growth.

Mixed signals from cash flow and earnings

A separate analysis from Simply Wall St, dated September 2, 2026, points out that Illumina stock appears inexpensive on cash flow metrics but expensive when measured against earnings-based multiples. The analysis calculates an intrinsic value of about USD 261 per share based on discounted cash flow, which is roughly 26.0 percent above the current USD 207.13 share price, while earnings ratios paint a less favorable picture.

In that context, the authors note that Illumina has delivered a strong 111.7 percent share price gain over the past year, again using USD 207.13 as the reference price as of September 2, 2026. Compared with the mid-2025 level of USD 109.30 quoted by StockInvest.us, this implies a near doubling of the stock price within roughly twelve months, a performance that raises questions about how much of the company’s long-term growth potential is already priced in.

Institutional interest and DACH perspective

Recent filings summarized by MarketBeat on September 2, 2026, indicate that institutional investors such as the Public Employees Retirement System of Ohio hold positions in Illumina, with an investment of around USD 7.86 million. While such stakes are modest relative to the company’s overall market capitalization, they show that large portfolios continue to include Illumina in their exposure to life-science tools and diagnostics.

For investors in the DACH region, Illumina’s primary trading venue remains the Nasdaq listing in the United States, and the stock is commonly used as a genomic sequencing peer when German and Swiss banks analyze health care and medtech exposure. At the current USD 207.13 level, the stock’s strong recovery from mid-2025 prices may influence how DACH analysts assess comparable companies in Europe’s diagnostics and laboratory equipment space, even though Illumina itself is not part of a DAX or SMI index.

Sequencing platforms and oncology partnerships

Illumina’s core business centers on next-generation sequencing platforms and associated consumables used by research institutions, clinical laboratories and biopharmaceutical companies. A recent overview on Yahoo Finance’s Singapore portal notes that Illumina has formed a partnership with Labcorp Holdings to develop oncology treatments that leverage sequencing solutions across the health care landscape, underscoring the company’s strategic focus on precision oncology and companion diagnostics.

In addition to oncology, Illumina is expanding into spatial transcriptomics, as demonstrated by its StrataMap Spatial Transcriptome solution presented on the company’s video hub on September 2, 2026. The platform aims to combine gene-expression data with spatial information in tissue samples, a capability that could support drug discovery and biomarker identification. For investors, the commercial success of such products will be critical to sustaining revenue growth that can justify the stock’s premium valuation metrics.

Illumina stock and recent price performance

As of September 1, 2026, Illumina’s share price of USD 207.13 compares with the July 25, 2025 closing price of USD 109.30, implying a gain of USD 97.83 per share over that period. Expressed in percentage terms, this represents an increase of about 89.6 percent, illustrating how strongly the market has re-rated the genomic sequencing specialist over the past year.

For retail investors, this pronounced move means that Illumina stock now sits closer to some optimistic intrinsic value estimates, such as the USD 261 per share cash flow based valuation cited by Simply Wall St, while trading significantly above more cautious benchmarks like the GF Value level of USD 132.60 mentioned by GuruFocus. The spread between these valuation anchors and the live market price highlights the uncertainty surrounding Illumina’s long-term earnings power and the extent to which future growth is already anticipated in the share price.